Improving vasculoprotective effects of MSCs in coronary microvessels - benefits of 3D culture, sub-populations and heparin.
coronary microcirculation
intravital microscopy
mesenchymal stem/stromal cells
myocardial infarction
myocardial ischaemia-reperfusion injury
neutrophils
platelets
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
07
2023
accepted:
02
10
2023
medline:
14
11
2023
pubmed:
13
11
2023
entrez:
13
11
2023
Statut:
epublish
Résumé
Opening occluded coronary arteries in patients with myocardial infarction (MI) damages the delicate coronary microvessels through a process called myocardial ischaemia-reperfusion injury. Although mesenchymal stromal cells (MSCs) have the potential to limit this injury, clinical success remains limited. This may be due to (i) poor MSC homing to the heart (ii) infused MSCs, even if derived from the same site, being a heterogeneous population with varying therapeutic efficacy and (iii) conventional 2D culture of MSCs decreasing their homing and beneficial properties. This study investigated whether 3D culture of two distinctly different bone marrow (BM)-derived MSC sub-populations could improve their homing and coronary vasculoprotective efficacy. Intravital imaging of the anaesthetised mouse beating heart was used to investigate the trafficking and microvascular protective effects of two clonally-derived BM-derived MSC lines, namely CD317 3D culture consistently improved the adhesive behaviour of MSCs-Y201 to various substrates This novel study highlights the importance of not only 3D culture, but also of a specific CD317
Identifiants
pubmed: 37954606
doi: 10.3389/fimmu.2023.1257497
pmc: PMC10635425
doi:
Substances chimiques
Heparin
9005-49-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1257497Subventions
Organisme : British Heart Foundation
ID : PG/14/92/31234
Pays : United Kingdom
Organisme : Department of Health
ID : NIHR203326
Pays : United Kingdom
Informations de copyright
Copyright © 2023 Bumroongthai, Kavanagh, Genever and Kalia.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cell Adh Migr. 2012 Mar-Apr;6(2):71-7
pubmed: 22568952
Theranostics. 2019 Aug 14;9(21):6112-6128
pubmed: 31534540
JCI Insight. 2022 Mar 8;7(5):
pubmed: 35113814
J Cell Biochem. 2012 Sep;113(9):2806-12
pubmed: 22511358
PLoS One. 2013 Jun 19;8(6):e66489
pubmed: 23840488
N Engl J Med. 2007 Feb 22;356(8):830-40
pubmed: 17314342
Circulation. 2004 Mar 9;109(9):1121-6
pubmed: 14967718
Eur Heart J. 2017 Mar 14;38(11):774-784
pubmed: 27354052
Vasc Dis Prev. 2010;7:1-14
pubmed: 25558187
Circulation. 2001 Jul 17;104(3):253-6
pubmed: 11457740
Stem Cells Transl Med. 2013 Aug;2(8):584-94
pubmed: 23847001
Gut. 2010 Jan;59(1):79-87
pubmed: 19828466
Heart. 2016 Mar;102(5):341-8
pubmed: 26674987
Cell Death Dis. 2020 May 11;11(5):349
pubmed: 32393744
Front Immunol. 2019 Nov 26;10:2782
pubmed: 31849965
Stem Cell Res Ther. 2017 Apr 26;8(1):94
pubmed: 28446248
Cardiovasc Res. 2019 Nov 1;115(13):1918-1932
pubmed: 31062860
Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13724-9
pubmed: 20643923
Ann Thorac Surg. 1996 Dec;62(6):1868-75
pubmed: 8957415
Cardiovasc Res. 2019 Jun 1;115(7):1143-1155
pubmed: 30428011
Nat Rev Cardiol. 2014 Nov;11(11):671-83
pubmed: 25267423
J Biol Chem. 2012 Feb 17;287(8):5542-53
pubmed: 22194593
Am J Cardiol. 2010 Sep 1;106(5):635-40
pubmed: 20723637
Cell Tissue Res. 2013 Apr;352(1):123-31
pubmed: 22729488
Microvasc Res. 2019 Jan;121:63-70
pubmed: 30343002
Eur Heart J. 2017 Feb 14;38(7):478-488
pubmed: 26843279
Pharm Biol. 2015 Jan;53(1):72-7
pubmed: 25289529
iScience. 2019 May 31;15:421-438
pubmed: 31121468
Stem Cell Rev Rep. 2020 Oct;16(5):853-875
pubmed: 32681232
Eur Heart J. 2016 Apr 1;37(13):1024-33
pubmed: 26364289
Cell Prolif. 2017 Apr;50(2):
pubmed: 27878916
J Am Coll Cardiol. 2016 Apr 12;67(14):1674-83
pubmed: 27056772
Front Immunol. 2022 Jun 06;13:903796
pubmed: 35734183
Tissue Eng Part B Rev. 2014 Oct;20(5):365-80
pubmed: 24168395
Nat Rev Cardiol. 2020 Dec;17(12):773-789
pubmed: 32620851
Mol Ther. 2012 Jan;20(1):14-20
pubmed: 22008910
Biophys J. 2009 Jul 8;97(1):379-87
pubmed: 19580776
J Biol Chem. 2008 May 9;283(19):13100-7
pubmed: 18334485
Eur Heart J. 2017 Apr 1;38(13):935-941
pubmed: 27118196
Stem Cells Dev. 2014 May 1;23(9):978-89
pubmed: 24341685
J Anat. 2023 Jan;242(1):3-16
pubmed: 34905637
J Clin Invest. 2013 Jan;123(1):92-100
pubmed: 23281415
Am J Physiol Heart Circ Physiol. 2000 Dec;279(6):H2581-4
pubmed: 11087206
Int J Mol Sci. 2021 Jan 15;22(2):
pubmed: 33467726
J Cell Mol Med. 2017 Jun;21(6):1073-1084
pubmed: 28276635
J Transl Med. 2008 Oct 09;6:57
pubmed: 18844982
Future Virol. 2013 Nov;8(11):
pubmed: 24396393
Theranostics. 2017 Jan 1;7(1):106-116
pubmed: 28042320
Stem Cell Reports. 2015 Jun 9;4(6):1004-15
pubmed: 26070611
Stem Cells Transl Med. 2020 Sep;9(9):985-1006
pubmed: 32497410
PLoS One. 2019 Mar 11;14(3):e0213162
pubmed: 30856207
Stem Cells. 2012 Oct;30(10):2283-96
pubmed: 22865689
PLoS One. 2018 Nov 13;13(11):e0203750
pubmed: 30422990
Stem Cell Rev Rep. 2014 Aug;10(4):587-99
pubmed: 24752328
Stem Cells. 2007 Jul;25(7):1761-8
pubmed: 17395769
Cell Transplant. 2013;22(8):1485-99
pubmed: 22889470
Curr Protoc Stem Cell Biol. 2014 Feb 06;28:2B.6.1-2B.6.23
pubmed: 24510769
Stem Cells Dev. 2009 Jun;18(5):683-92
pubmed: 19099374
PLoS One. 2013;8(3):e59150
pubmed: 23554986